CardioExchange Archive

The COMPARE trial, published online in the Lancet, found that everolimus-eluting stents outperformed paclitaxel-eluting stents. The COMPARE investigators “suggest that paclitaxel-eluting stents should no longer be used in everyday clinical practice.” CardioBrief has an interesting comment from David Kandzari.The FDA released briefing documents for Monday’s Cardiovascular and Renal Drugs Advisory Committee meeting to review a heart failure indication for nebivolol (Bystolic). In an unusual move, the FDA reviewers issued an unambiguous negative recommendation.Vivus, a small Biopharmaceutical company, announced positive results from a phase 2 trial showing that its much discussed obesity drug, Qnexa (phentermine and topiramate), significantly reduced the number of sleep apnea events. (Vivus press release)